Literature DB >> 20936700

Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model.

Yusuke Seino1, Takeshi Kawarabayashi, Yasuhito Wakasaya, Mitsunori Watanabe, Ayumi Takamura, Yukiko Yamamoto-Watanabe, Tomoko Kurata, Koji Abe, Masaki Ikeda, David Westaway, Tetsuro Murakami, Peter St George Hyslop, Etsuro Matsubara, Mikio Shoji.   

Abstract

In Alzheimer's disease, Aβ deposits are considered the initial cardinal events that induce tauopathy secondarily. However, the relationship between Aβ amyloidosis and tauopathy has not been determined in detail. We produced double transgenic mice, 2×TgTau(+/-) APP(+/-) , by mating Tg2576 mice that exhibit Aβ amyloidosis and TgTauP301L mice that show tauopathy, and statistically analyzed the effect of Aβ accumulation on tauopathy. There was no significant difference in theprogression of Aβ accumulation among 2×TgTau(+/-) APP(+/-) and 1×TgTau(-/-) APP(+/-) , and tau accumulation among 2×TgTau(+/-) APP(+/-) and 1×Tg Tau(+/-) APP(-/-) . The appearance rates of phosphorylated tau developing in neurons and processes were significantly accelerated in 2×TgTau(+/-) APP(+/-) mice compared with those in 1×TgTau(+/-) APP(-/-) mice at 23 months of age. Accumulation of phosphorylated and confomationally altered tau and GSK3β in neuronal processes was accelerated in the white matter in 2×TgTau(+/-) APP(+/-) . The level of phosphorylated tau in the sarkosyl-insoluble fraction was increased in 2×TgTau(+/-) APP(+/-) brains compared with that in 1×TgTau(+/-) APP(-/-) brains. Thus, Aβ amyloid partially enhances tauopathy through accumulation of insoluble, phosphorylated, and conformationally changed tau in neuronal cytoplasm and processes in the late stage.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936700     DOI: 10.1002/jnr.22516

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

Review 1.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

2.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  Enhanced Tau Aggregation in the Presence of Amyloid β.

Authors:  Rachel E Bennett; Sarah L DeVos; Simon Dujardin; Bianca Corjuc; Rucha Gor; Jose Gonzalez; Allyson D Roe; Matthew P Frosch; Rose Pitstick; George A Carlson; Bradley T Hyman
Journal:  Am J Pathol       Date:  2017-05-10       Impact factor: 4.307

4.  Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?

Authors:  Shaoxun Wang; Paige N Mims; Richard J Roman; Fan Fan
Journal:  J Alzheimers Parkinsonism Dement       Date:  2016-11-17

Review 5.  Alzheimer disease: a tale of two prions.

Authors:  Justin M Nussbaum; Matthew E Seward; George S Bloom
Journal:  Prion       Date:  2012-09-10       Impact factor: 3.931

6.  P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating.

Authors:  Hiroki Takeuchi; Michiyo Iba; Haruhisa Inoue; Makoto Higuchi; Keizo Takao; Kayoko Tsukita; Yoshiko Karatsu; Yumiko Iwamoto; Tsuyoshi Miyakawa; Tetsuya Suhara; John Q Trojanowski; Virginia M-Y Lee; Ryosuke Takahashi
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

7.  Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease.

Authors:  Qiankun Quan; Xi Li; Jianjun Feng; Jixing Hou; Ming Li; Bingwei Zhang
Journal:  Mol Med Rep       Date:  2020-08-07       Impact factor: 2.952

8.  Early active immunization with Aβ3-10-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice.

Authors:  Jin-Chun Wang; Kun Zhu; Hui-Yi Zhang; Guo-Qing Wang; Hui-Ying Liu; Yun-Peng Cao
Journal:  Neural Regen Res       Date:  2020-03       Impact factor: 5.135

9.  mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Authors:  Carol A Colton; Joan G Wilson; Angela Everhart; Donna M Wilcock; Jukka Puoliväli; Taneli Heikkinen; Juho Oksman; Olli Jääskeläinen; Kimmo Lehtimäki; Teemu Laitinen; Nina Vartiainen; Michael P Vitek
Journal:  J Neuropathol Exp Neurol       Date:  2014-08       Impact factor: 3.685

10.  Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.

Authors:  Sumihiro Maeda; Biljana Djukic; Praveen Taneja; Gui-Qiu Yu; Iris Lo; Allyson Davis; Ryan Craft; Weikun Guo; Xin Wang; Daniel Kim; Ravikumar Ponnusamy; T Michael Gill; Eliezer Masliah; Lennart Mucke
Journal:  EMBO Rep       Date:  2016-03-01       Impact factor: 8.807

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.